In this study, we investigated using a CHK1 inhibitor as a DNA damaging agent to decrease Mcl-1 protein levels and enhance ABT-199 sensitivity in AML cells, based on a previous report that DNA damage can cause decreased expression of Mcl-1 in cancer cells [26]. The gene discussed is MCL1; the disease is acute myeloid leukemia.